Skip to main content
. 2011 Mar 15;52(6):726–735. doi: 10.1093/cid/ciq245

Table 5.

Multivariate Logistic Regression Analysis of the Probability of Death within 1 Year for Patients Unresponsive to Initial Immunosuppressive Therapy

Risk factor Effect of covariate and risk of deatha
Effect of antifungal therapyb
Baseline risk Coefficient (β) SD OR P Coefficient (β) SD OR P
Age 0.033 0.012 1.034 .004 0.064 0.024 1.066 .007
ANC <200 cells/μL 2.056 0.633 7.818 .001 2.623 1.234 13.777 .034
ARC 0.114 0.234 1.120 .627
ALC -.297 0.399 0.743 .457
Platelet count -.096 0.267 0.908 .719
Bacteremia only 0.919 0.542 2.508 .090
Fungal infection 2.751 0.665 15.666 <.001
Voriconazole -2.550 0.967 0.078 .008

NOTE. The bacteremia-only group did not include patients with a concomitant fungal infection. Fungal groups were those who had a fungal isolate identified in blood, secretions, and/or tissue (seeTable 4). The amphotericin B group does not include liposomal formulations. Voriconazole refers to any voriconazole-containing regimen. Natural log-transformed counts log(ANC+1), log(ARC+1), log(ALC+1), and log(platelet+1) were used to reduce the skewness of these variables. ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ARC, absolute reticulocyte count; OR, odds ratio; SD, standard deviation.

a

Includes age, ANC, ARC, ALC, Platelet count, bacteremia-only infection, and fungal infection.

b

After fungal infection was found to be an independent variable predicting probability of death, a separate analysis was performed to assess the effect of voriconazole vs amphotericin B as a predictor of death (includes age, ANC, and antifungal therapy defined by 0 if amphotericin B was used and 1 if a voriconazole-containing regimen was used). There were insufficient numbers of patients receiving echinocandins to be included in this analysis. Covariates not statistically significant in the first analysis were not included in the antifungal analysis.